May 2nd 2024
Kamuvudine-8, also known as K8, is administered to the back of the eye via a sustained released intravitreal implant.
Caroline Baumal, Chief Medical Officer at Apellis, spoke with Ophthalmology Times on the GALE extension study of pegcetacoplan for geographic atrophy, and shared insights on her career transition, emphasizing the significance of mentorship and a passion for one’s work at this year's American Academy of Ophthalmology meeting in San Francisco.
Read More
Clinical characteristics and progression of Geographic Atrophy in a Japanese population
November 7th 2023This retrospective, multicenter, observational study examined Japanese patients with GA to determine the clinical characteristics and GA progression rate associated with AMD in an Asian population.
Read More
Pegcetacoplan shows increasing beneficial effects after 30 Months of Continuous treatment for GA
August 2nd 2023Data from the 30 month GALE extension study indicated that continuous treatment with pegcetacoplan injection showed increasing beneficial effects over that timeframe in patients with geographic atrophy (GA).
Read More